Research Analysts Offer Predictions for MariMed Q1 Earnings

MariMed Inc. (OTCMKTS:MRMD) – Noble Financial issued their Q1 2025 earnings per share (EPS) estimates for MariMed in a report issued on Thursday, April 3rd. Noble Financial analyst J. Gomes expects that the company will post earnings per share of ($0.01) for the quarter. Noble Financial has a “Strong-Buy” rating on the stock. Noble Financial also issued estimates for MariMed’s Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at $0.00 EPS, FY2025 earnings at ($0.01) EPS and FY2026 earnings at $0.02 EPS.

MariMed (OTCMKTS:MRMD) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). MariMed had a negative return on equity of 2.75% and a negative net margin of 10.97%. The business had revenue of $39.00 million for the quarter, compared to analyst estimates of $42.00 million.

MariMed Price Performance

Shares of MRMD stock opened at $0.09 on Monday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.55 and a quick ratio of 0.73. The company has a market capitalization of $32.43 million, a PE ratio of -2.13 and a beta of 2.75. The firm’s 50-day moving average is $0.11 and its two-hundred day moving average is $0.13. MariMed has a 12 month low of $0.07 and a 12 month high of $0.34.

About MariMed

MariMed Inc engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand.